Abstracts of the 2012 Joanna Briggs Institute International Colloquium 287 these drugs in secondary prevention of mortality and cardiovascular events in patients with Acute Coronary Syndrome (ACS) have still not been fully clarifi ed. Objective: to analyze the benefi ts of using statins compared to placebo or usual care in patients with ACS on the reduction of mortality from all causes, mortality cardiovascular, myocardial infarction (fatal and non-fatal), percutaneous coronary intervention, revascularization and hospitalization. Database: this is a systematic review completed on January 29, 2012, whose selection of randomized and controlled clinical trials (ECCR) was held in electronic databases MEDLINE, EMBASE, PubMed/Cochrane Central, LILACS and Theses database-CAPES. Data collection: two researchers performed the extraction of information about Basal characteristics of included studies, evaluation of methodological quality and outcomes not independently combined. Results: were included in the meta-analysis, involving 18 ECCR 15,370 patients with ACS. The use of statins has shown benefi t in reducing mortality from all causes, risk difference (rd) = −0.0066 and hospitalization rd = −0.0101. As to cardiovascular, myocardial infarction fatal and non-fatal coronary intervention, and percutaneous revascularization mortality outcomes, there was no statistically signifi cant difference between the groups statins versus placebo or usual care. Conclusions: the available evidence suggests that statins cause a reduction in mortality from all causes and hospitalization, but do not demonstrate difference when compared to placebo or usual care in other important events.

No abstract

No abstract

The original article was updated to include co-author Koen F. den Brok's middle initial in the author list. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

No abstract